VANGUARD GROUP INC - FATE THERAPEUTICS INC ownership

FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 74 filers reported holding FATE THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
VANGUARD GROUP INC ownership history of FATE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$23,125,704
-58.6%
10,908,351
-7.0%
0.00%0.0%
Q2 2023$55,803,260
-10.7%
11,723,374
+7.0%
0.00%
-50.0%
Q1 2023$62,477,397
-22.3%
10,960,947
+37.5%
0.00%0.0%
Q4 2022$80,443,039
-54.1%
7,972,551
+2.0%
0.00%
-60.0%
Q3 2022$175,133,000
-8.9%
7,814,980
+0.7%
0.01%0.0%
Q2 2022$192,241,000
-35.5%
7,757,940
+0.9%
0.01%
-28.6%
Q1 2022$298,187,000
-33.6%
7,691,172
+0.2%
0.01%
-30.0%
Q4 2021$449,109,000
-0.6%
7,675,787
+0.6%
0.01%
-9.1%
Q3 2021$452,012,000
-31.2%
7,626,346
+0.7%
0.01%
-31.2%
Q2 2021$657,060,000
+6.6%
7,570,681
+1.3%
0.02%
-5.9%
Q1 2021$616,358,000
-0.0%
7,475,537
+10.3%
0.02%
-5.6%
Q4 2020$616,376,000
+145.7%
6,778,587
+8.0%
0.02%
+125.0%
Q3 2020$250,855,000
+43.4%
6,276,062
+23.1%
0.01%
+33.3%
Q2 2020$174,932,000
+142.3%
5,098,551
+56.8%
0.01%
+100.0%
Q1 2020$72,197,000
+18.1%
3,250,622
+4.0%
0.00%
+50.0%
Q4 2019$61,151,000
+29.0%
3,124,769
+2.4%
0.00%0.0%
Q3 2019$47,403,000
-14.4%
3,052,352
+11.9%
0.00%0.0%
Q2 2019$55,378,000
+15.8%
2,727,990
+0.2%
0.00%0.0%
Q1 2019$47,823,000
+46.6%
2,721,844
+7.1%
0.00%
+100.0%
Q4 2018$32,613,000
-18.2%
2,541,990
+3.8%
0.00%
-50.0%
Q3 2018$39,882,000
+61.9%
2,448,279
+12.7%
0.00%
+100.0%
Q2 2018$24,636,000
+38.9%
2,172,451
+19.5%
0.00%0.0%
Q1 2018$17,741,000
+99.0%
1,817,721
+24.6%
0.00%
Q4 2017$8,916,000
+75.5%
1,459,136
+13.7%
0.00%
Q3 2017$5,080,000
+24.0%
1,282,993
+1.5%
0.00%
Q2 2017$4,096,000
-22.1%
1,264,281
+9.4%
0.00%
Q1 2017$5,258,000
+231.5%
1,155,679
+82.9%
0.00%
Q4 2016$1,586,000
-26.1%
631,995
-8.1%
0.00%
Q3 2016$2,145,000
+91.9%
687,693
+4.6%
0.00%
Q2 2016$1,118,000
-2.3%
657,573
+3.5%
0.00%
Q1 2016$1,144,000
-18.2%
635,475
+53.0%
0.00%
Q4 2015$1,399,000
-99.1%
415,243
-91.8%
0.00%
-100.0%
Q3 2015$148,487,000
+6705.1%
5,060,786
+1400.7%
0.01%
Q2 2015$2,182,000
+147.1%
337,238
+86.7%
0.00%
Q1 2015$883,000
+2.1%
180,638
+5.1%
0.00%
Q4 2014$865,000
-2.1%
171,9380.0%0.00%
Q3 2014$884,000
-5.8%
171,938
+15.7%
0.00%
Q2 2014$938,000
-35.2%
148,6060.0%0.00%
Q1 2014$1,447,000
+1147.4%
148,606
+702.1%
0.00%
Q4 2013$116,00018,5260.00%
Other shareholders
FATE THERAPEUTICS INC shareholders Q3 2017
NameSharesValueWeighting ↓
JOHNSON & JOHNSON 3,379,064$7,163,6162.64%
Redmile Group, LLC 13,124,427$27,823,7851.32%
Monaco Asset Management SAM 1,847,944$3,917,6411.16%
Casdin Capital, LLC 2,050,000$4,346,0000.48%
TANG CAPITAL MANAGEMENT LLC 700,000$1,484,0000.21%
GCM Grosvenor Holdings, LLC 495,916$1,051,3420.21%
Nebula Research & Development LLC 163,617$346,8680.18%
Bellevue Group AG 4,851,579$10,285,3470.17%
Bruce & Co., Inc. 200,000$424,0000.14%
XTX Topco Ltd 192,920$408,9900.07%
View complete list of FATE THERAPEUTICS INC shareholders